20.09 USD
-0.29 (-1.42%)
20.09 USD
0 (0%)
PCRX gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 190 industry peers in the Pharmaceuticals industry. While PCRX belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. PCRX is valued quite cheap, but it does not seem to be growing. These ratings could make PCRX a good candidate for value investing.
1. Profitability
1.1 Basic Checks
- In the past year PCRX was profitable.
- PCRX had a positive operating cash flow in the past year.
- Of the past 5 years PCRX 4 years were profitable.
- In the past 5 years PCRX always reported a positive cash flow from operatings.
1.2 Ratios
- PCRX has a Return On Assets of 1.65%. This is amongst the best in the industry. PCRX outperforms 81.05% of its industry peers.
- Looking at the Return On Equity, with a value of 2.95%, PCRX belongs to the top of the industry, outperforming 82.11% of the companies in the same industry.
- PCRX has a Return On Invested Capital of 3.63%. This is amongst the best in the industry. PCRX outperforms 81.58% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for PCRX is significantly below the industry average of 12.83%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.65% | ||
| ROE | 2.95% | ||
| ROIC | 3.63% |
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.3%
ROIC(5y)4.55%
1.3 Margins
- Looking at the Profit Margin, with a value of 2.99%, PCRX is in the better half of the industry, outperforming 79.47% of the companies in the same industry.
- PCRX has a better Operating Margin (8.88%) than 81.05% of its industry peers.
- PCRX's Operating Margin has improved in the last couple of years.
- PCRX's Gross Margin of 79.17% is amongst the best of the industry. PCRX outperforms 84.21% of its industry peers.
- In the last couple of years the Gross Margin of PCRX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.88% | ||
| PM (TTM) | 2.99% | ||
| GM | 79.17% |
OM growth 3Y-15.96%
OM growth 5Y11.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PCRX is destroying value.
- PCRX has less shares outstanding than it did 1 year ago.
- PCRX has more shares outstanding than it did 5 years ago.
- PCRX has a worse debt/assets ratio than last year.
2.2 Solvency
- An Altman-Z score of 1.84 indicates that PCRX is not a great score, but indicates only limited risk for bankruptcy at the moment.
- The Altman-Z score of PCRX (1.84) is comparable to the rest of the industry.
- The Debt to FCF ratio of PCRX is 3.03, which is a good value as it means it would take PCRX, 3.03 years of fcf income to pay off all of its debts.
- PCRX's Debt to FCF ratio of 3.03 is amongst the best of the industry. PCRX outperforms 90.53% of its industry peers.
- A Debt/Equity ratio of 0.52 indicates that PCRX is somewhat dependend on debt financing.
- PCRX has a worse Debt to Equity ratio (0.52) than 63.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 3.03 | ||
| Altman-Z | 1.84 |
ROIC/WACC0.46
WACC7.83%
2.3 Liquidity
- A Current Ratio of 5.26 indicates that PCRX has no problem at all paying its short term obligations.
- With a decent Current ratio value of 5.26, PCRX is doing good in the industry, outperforming 64.74% of the companies in the same industry.
- A Quick Ratio of 3.78 indicates that PCRX has no problem at all paying its short term obligations.
- Looking at the Quick ratio, with a value of 3.78, PCRX is in line with its industry, outperforming 60.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.26 | ||
| Quick Ratio | 3.78 |
3. Growth
3.1 Past
- The earnings per share for PCRX have decreased by -6.90% in the last year.
- PCRX shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 13.96% yearly.
- PCRX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -16.85%.
- PCRX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.73% yearly.
EPS 1Y (TTM)-6.9%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%-11.39%
Revenue 1Y (TTM)-16.85%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%6.49%
3.2 Future
- The Earnings Per Share is expected to grow by 7.01% on average over the next years.
- PCRX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.38% yearly.
EPS Next Y-6.13%
EPS Next 2Y4.05%
EPS Next 3Y6.92%
EPS Next 5Y7.01%
Revenue Next Year4.33%
Revenue Next 2Y6.28%
Revenue Next 3Y7.3%
Revenue Next 5Y6.38%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 6.76, the valuation of PCRX can be described as very cheap.
- 93.68% of the companies in the same industry are more expensive than PCRX, based on the Price/Earnings ratio.
- PCRX's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 28.60.
- Based on the Price/Forward Earnings ratio of 5.78, the valuation of PCRX can be described as very cheap.
- PCRX's Price/Forward Earnings ratio is rather cheap when compared to the industry. PCRX is cheaper than 93.16% of the companies in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 25.83. PCRX is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.76 | ||
| Fwd PE | 5.78 |
4.2 Price Multiples
- PCRX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. PCRX is cheaper than 96.32% of the companies in the same industry.
- PCRX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. PCRX is cheaper than 96.32% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.96 | ||
| EV/EBITDA | 5.88 |
4.3 Compensation for Growth
- The decent profitability rating of PCRX may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.48
EPS Next 2Y4.05%
EPS Next 3Y6.92%
5. Dividend
5.1 Amount
- No dividends for PCRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
PACIRA BIOSCIENCES INC / PCRX FAQ
What is the ChartMill fundamental rating of PACIRA BIOSCIENCES INC (PCRX) stock?
ChartMill assigns a fundamental rating of 6 / 10 to PCRX.
What is the valuation status for PCRX stock?
ChartMill assigns a valuation rating of 8 / 10 to PACIRA BIOSCIENCES INC (PCRX). This can be considered as Undervalued.
How profitable is PACIRA BIOSCIENCES INC (PCRX) stock?
PACIRA BIOSCIENCES INC (PCRX) has a profitability rating of 7 / 10.
What is the valuation of PACIRA BIOSCIENCES INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for PACIRA BIOSCIENCES INC (PCRX) is 6.76 and the Price/Book (PB) ratio is 1.19.